
Disrupep lanza una campaña de crowdfunding para avanzar en la investigación y prevención del estrés postraumático (TEPT)
Desde Disrupep hemos puesto en marcha una campaña de crowdfunding con el objetivo de recaudar
DisruPep S.L. was born in 2020 as a spanish biotech with technology for the development of peptide-based drugs. DisruPep is a spin-off Technology-Based Company of the Neuroscience Cajal Centre (CNC-CSIC) in Madrid with an important laboratory of neuroscience. The CNC, old Cajal Institute, was the oldest institute from the Spanish National Research Council (Consejo Superior de Investigaciones Científicas, CSIC), which is the largest public institution dedicated to research in Spain and the third largest in Europe. DisruPep was originally created with the purpose of developing and exploiting a patent license for a drug candidate for post-traumatic stress disorder: the QBP1 peptide. Currently, the company develops also other drugs and products of of high biomedical interest.
The company builts up on the accumulated knowledge of more than a decade of research of the laboratory of Dr. Carrión Vázquez working, in the field of amyloid diseases. We have the challenge of developing drugs to the help millions of people who suffer from those diseases by developing disruptive medicines directed to therapeutic targets placed at the start of the amyloid cascade.
Company with Technological Base (EBT), Spin-Off from CSIC
Lorem ipsum dolor sit amet consectetur adipiscing elit.
Lorem ipsum dolor sit amet consecte adipiscing.
Lorem ipsum dolor sit amet consecte adipiscing.
Lorem ipsum dolor sit amet consecte adipiscing.
Lorem ipsum dolor sit amet consecte adipiscing.
Lorem ipsum dolor sit amet consecte adipiscing.
Lorem ipsum dolor sit amet consecte adipiscing.
Lorem ipsum dolor sit amet consecte adipiscing.
Lorem ipsum dolor sit amet consecte adipiscing.

Desde Disrupep hemos puesto en marcha una campaña de crowdfunding con el objetivo de recaudar

El próximo 25 de noviembre de 2026, Madrid acogerá TRAUMA360, un congreso gratuito que reunirá

Un estudio publicado en la prestigiosa revista científica Advanced Science (2026) demuestra la eficacia preclínica
Email: mcarrion@cajal.csic.es
Dont like Filling up forms ? Mail us then
Data controller: Disrupep s.l., responsible for this website Purpose of the data: Manage the request you make in this contact form. Data storage: Database hosted on siteground spain sl Rights: At any time you can limit, recover and delete your information. For more information: Privacy Policy